July 25, 1996New England Journal of Medicine336 citationsOpen Access

Cisapride and Fatal Arrhythmia

Key Points

Key points are not available for this paper at this time.

Abstract

To the Editor: From September 1993, the month in which the marketing of cisapride (Propulsid, Janssen Pharmaceutica, Titusville, N.J.) began, to April 1996, the Food and Drug Administration's MedWa...

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Wysowski et al. (1996) studied this question.

synapsesocial.com/papers/6a753a5e9c92392688b20b04 https://doi.org/10.1056/nejm199607253350416

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Contractile Function and Response to Agonists in Myocytes from Failing Human Heart1994 · 13 citations
2Intracellular calcium and ventricular fibrillation. Studies in the aequorin-loaded isovolumic ferret heart.1991 · 102 citations
3Cellular origins of the transient inward current in cardiac myocytes. Role of fluctuations and waves of elevated intracellular calcium.1989 · 225 citations
4Long QT syndrome during high-dose cisapride1995 · 27 citations
5Tachycardia during cisapride treatment.1992 · 109 citations

Ask AI

Helpful

Bookmark

View Full Paper